YC W22
Actipulse Neuroscience
Bringing non-invasive brain stimulation from the hospital to the home
About
Non-invasive brain stimulation is a widely-utilized, FDA cleared treatment used for patients diagnosed with depression, but is limited to a hospital setting due to the cost of the device, and complexity of treatment application. Our proprietary brain stimulation device allows patients to be treated directly from their home, with the same efficacy, and at a lower cost of treatment. Currently in FDA pivotal phase for Major Depressive Disorder, and Pilot phase for Alzheimer's and Parkinson diseases.
Founders
- Adrien Châtillon
Family Office Investors
Altss tracks family office allocations to YC-backed companies. Request access to see which family offices have invested in Actipulse Neuroscience.
See family office activityIndustry & Focus
HealthcareMedical DevicesMental Health TechNeurotechnology